LOS ANGELES — At the American Society of Cataract and Refractive Surgery meeting, Jennifer M. Loh, MD, discussed 24-month data investigating TearCare, a localized heat therapy treatment for dry eye disease, compared with Restasis.
Stage 1 of the SAHARA trial found that outcomes in patients randomly assigned to treatment with TearCare (Sight Sciences) were superior in terms of tear breakup time and meibomian gland secretion scores vs. Restasis (cyclosporine ophthalmic emulsion 0.05%, AbbVie).
“Both groups showed improvement in the OSDI, or patient symptomatic questionnaire score,”